Taiwanese biotech company

TaiMed Biologics is a leading Taiwanese biotechnology company focused on the discovery and development of innovative biologics for the treatment of infectious diseases, particularly HIV/AIDS. The company's flagship product, Trogarzo (ibalizumab-uiyk), is a first-in-class CD4-directed post-attachment HIV-1 inhibitor and was the first drug developed by a Taiwanese company to receive U.S. FDA approval. TaiMed maintains a robust pipeline of long-acting monoclonal antibodies, including TMB-365 and TMB-380, aimed at providing simplified maintenance therapies for patients living with HIV. Headquartered in Taipei, the company operates state-of-the-art cGMP manufacturing facilities and collaborates with global partners to commercialize its therapies worldwide. TaiMed's mission is to address significant unmet medical needs in the field of virology through cutting-edge antibody engineering.